Gold rally may be losing steam but no major correction seen: DB
MENLO PARK, Calif. - PacBio (NASDAQ:PACB), a $456 million market cap genomics company whose stock has surged nearly 19% in the past week, announced Tuesday an expanded partnership with seqWell to distribute the LongPlex Multiplexing Kit, a sample preparation solution designed for PacBio HiFi sequencing. According to InvestingPro data, the company’s stock has shown significant momentum recently, though it remains volatile.
The agreement allows PacBio to offer seqWell’s technology that enables researchers to simultaneously fragment and index DNA for up to hundreds of samples in a single run, addressing sample preparation bottlenecks in genomic research. While the company maintains strong liquidity with a current ratio of 6.92, InvestingPro analysis indicates the company is quickly burning through cash, which could impact future operations.
The LongPlex kit uses tagmentation technology to support high-throughput applications including low-pass whole genome sequencing, plasmid sequencing, and microbial sequencing.
"Expanding our partnership with seqWell is part of our commitment to meet researchers where they are with the flexibility, speed, and accuracy they need," said David Miller, Vice President of Global Marketing at PacBio, according to the press release.
The collaboration aims to provide researchers with additional workflow options that complement PacBio’s long-read sequencing technology, particularly for large-scale screening and targeted resequencing efforts.
Veil Genomics, a company focused on population-scale low-pass whole genome sequencing, is already using the technology. Josh Clevenger, Co-founder of Veil Genomics, stated that the kit has allowed the company to process thousands of samples efficiently without compromising data quality.
The LongPlex Multiplexing Kit is currently available with global availability planned for 2026, according to the announcement.
PacBio develops sequencing solutions for researchers working across various fields including human germline sequencing, plant and animal sciences, infectious disease, and oncology. The company noted that its products are for research use only and not intended for diagnostic procedures.
In other recent news, Pacific Biosciences of California reported its financial results for the second quarter of 2025, surpassing revenue expectations. The company achieved a revenue of $39.8 million, exceeding the forecast of $36.66 million, marking an 8.57% surprise. Additionally, the earnings per share came in at a loss of $0.13, which was better than the anticipated loss of $0.17, representing a 23.53% surprise. In another development, Bernstein SocGen Group raised its price target for Pacific Biosciences to $1.70 from $1.50, maintaining an Outperform rating due to promising signs of clinical uptake for the company’s systems.
Furthermore, Pacific Biosciences announced its entry into the high-throughput carrier screening market with an expanded suite of PureTarget products. These new solutions aim to consolidate multiple specialized assays into a single test for analyzing challenging genes associated with inherited conditions. Additionally, PacBio partnered with EpiCypher, integrating EpiCypher’s CUTANA Hia5 enzyme with PacBio’s Fiber-seq assays, enhancing chromatin analysis capabilities. These recent developments indicate Pacific Biosciences’ ongoing efforts to expand its technological offerings and strengthen its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.